Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Distinct effects on diversifying selection by two mechanisms of immunity against Streptococcus pneumoniae.

Li Y, Gierahn T, Thompson CM, Trzciński K, Ford CB, Croucher N, Gouveia P, Flechtner JB, Malley R, Lipsitch M.

PLoS Pathog. 2012;8(11):e1002989. doi: 10.1371/journal.ppat.1002989. Epub 2012 Nov 8.

2.

T(H)17-based vaccine design for prevention of Streptococcus pneumoniae colonization.

Moffitt KL, Gierahn TM, Lu YJ, Gouveia P, Alderson M, Flechtner JB, Higgins DE, Malley R.

Cell Host Microbe. 2011 Feb 17;9(2):158-65. doi: 10.1016/j.chom.2011.01.007.

3.

Impaired innate and adaptive immunity to Streptococcus pneumoniae and its effect on colonization in an infant mouse model.

Bogaert D, Weinberger D, Thompson C, Lipsitch M, Malley R.

Infect Immun. 2009 Apr;77(4):1613-22. doi: 10.1128/IAI.00871-08. Epub 2009 Jan 21.

4.

Th17-Mediated Cross Protection against Pneumococcal Carriage by Vaccination with a Variable Antigen.

Kuipers K, Jong WSP, van der Gaast-de Jongh CE, Houben D, van Opzeeland F, Simonetti E, van Selm S, de Groot R, Koenders MI, Azarian T, Pupo E, van der Ley P, Langereis JD, Zomer A, Luirink J, de Jonge MI.

Infect Immun. 2017 Sep 20;85(10). pii: e00281-17. doi: 10.1128/IAI.00281-17. Print 2017 Oct.

PMID:
28717032
5.

Characterization of Th17 responses to Streptococcus pneumoniae in humans: comparisons between adults and children in a developed and a developing country.

Lundgren A, Bhuiyan TR, Novak D, Kaim J, Reske A, Lu YJ, Qadri F, Malley R.

Vaccine. 2012 Jun 6;30(26):3897-907. doi: 10.1016/j.vaccine.2012.03.082. Epub 2012 Apr 12.

6.

Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by Streptococcus pneumoniae.

Kong IG, Sato A, Yuki Y, Nochi T, Takahashi H, Sawada S, Mejima M, Kurokawa S, Okada K, Sato S, Briles DE, Kunisawa J, Inoue Y, Yamamoto M, Akiyoshi K, Kiyono H.

Infect Immun. 2013 May;81(5):1625-34. doi: 10.1128/IAI.00240-13. Epub 2013 Mar 4.

7.

Antibody and cell-mediated immunity to Streptococcus pneumoniae: implications for vaccine development.

Malley R.

J Mol Med (Berl). 2010 Feb;88(2):135-42. doi: 10.1007/s00109-009-0579-4. Epub 2010 Jan 5. Review.

PMID:
20049411
8.

Th17/Th1 biased immunity to the pneumococcal proteins PcsB, StkP and PsaA in adults of different age.

Schmid P, Selak S, Keller M, Luhan B, Magyarics Z, Seidel S, Schlick P, Reinisch C, Lingnau K, Nagy E, Grubeck-Loebenstein B.

Vaccine. 2011 May 23;29(23):3982-9. doi: 10.1016/j.vaccine.2011.03.081. Epub 2011 Apr 8.

PMID:
21481328
9.

Acquisition of pneumococci specific effector and regulatory Cd4+ T cells localising within human upper respiratory-tract mucosal lymphoid tissue.

Pido-Lopez J, Kwok WW, Mitchell TJ, Heyderman RS, Williams NA.

PLoS Pathog. 2011 Dec;7(12):e1002396. doi: 10.1371/journal.ppat.1002396. Epub 2011 Dec 1.

10.

Protection against nasopharyngeal colonization by Streptococcus pneumoniae is mediated by antigen-specific CD4+ T cells.

Trzciński K, Thompson CM, Srivastava A, Basset A, Malley R, Lipsitch M.

Infect Immun. 2008 Jun;76(6):2678-84. doi: 10.1128/IAI.00141-08. Epub 2008 Apr 7.

11.

Mechanisms in the serotype-independent pneumococcal immunity induced in mice by intranasal vaccination with the cell wall polysaccharide.

Lu YJ, Skovsted IC, Thompson CM, Anderson PW, Malley R.

Microb Pathog. 2009 Sep;47(3):177-82. doi: 10.1016/j.micpath.2009.06.008. Epub 2009 Jul 3.

12.

CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization.

Malley R, Trzcinski K, Srivastava A, Thompson CM, Anderson PW, Lipsitch M.

Proc Natl Acad Sci U S A. 2005 Mar 29;102(13):4848-53. Epub 2005 Mar 21.

13.

Risk of red queen dynamics in pneumococcal vaccine strategy.

Jefferies JM, Clarke SC, Webb JS, Kraaijeveld AR.

Trends Microbiol. 2011 Aug;19(8):377-81. doi: 10.1016/j.tim.2011.06.001. Epub 2011 Jul 15.

PMID:
21763141
14.
15.

Prevention of pneumococcal disease in mice immunized with conserved surface-accessible proteins.

Hamel J, Charland N, Pineau I, Ouellet C, Rioux S, Martin D, Brodeur BR.

Infect Immun. 2004 May;72(5):2659-70.

16.

Compound 48/80 acts as a potent mucosal adjuvant for vaccination against Streptococcus pneumoniae infection in young mice.

Zeng L, Liu Y, Wang H, Liao P, Song Z, Gao S, Wu Y, Zhang X, Yin Y, Xu W.

Vaccine. 2015 Feb 18;33(8):1008-16. doi: 10.1016/j.vaccine.2015.01.013. Epub 2015 Jan 14.

PMID:
25595867
17.

T cell memory response to pneumococcal protein antigens in an area of high pneumococcal carriage and disease.

Mureithi MW, Finn A, Ota MO, Zhang Q, Davenport V, Mitchell TJ, Williams NA, Adegbola RA, Heyderman RS.

J Infect Dis. 2009 Sep 1;200(5):783-93. doi: 10.1086/605023.

PMID:
19642930
18.

Timing of Toll-like receptor 9 agonist administration in pneumococcal vaccination impacts both humoral and cellular immune responses as well as nasopharyngeal colonization in mice.

Jensen KM, Melchjorsen J, Dagnaes-Hansen F, Sørensen UB, Laursen RR, Østergaard L, Søgaard OS, Tolstrup M.

Infect Immun. 2012 May;80(5):1744-52. doi: 10.1128/IAI.00079-12. Epub 2012 Feb 27. Erratum in: Infect Immun. 2014 Sep;82(9):3987. Dosage error in article text.

19.

Serotype-independent pneumococcal experimental vaccines that induce cellular as well as humoral immunity.

Malley R, Anderson PW.

Proc Natl Acad Sci U S A. 2012 Mar 6;109(10):3623-7. doi: 10.1073/pnas.1121383109. Epub 2012 Feb 2. Review.

20.

[Study of protective activity of Streptococcus pneumoniae protein-containing antigen complex in homologous system].

Vorob'ev DS, Semenova IB, Volokh IuV, Kudriashev AV, Markova ME, Romanenko ÉE, Baturo AP, Mikhaĭlova NA.

Zh Mikrobiol Epidemiol Immunobiol. 2013 Jan-Feb;(1):21-6. Russian.

PMID:
23805647

Supplemental Content

Support Center